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Abstract
Background: Valosin-containing protein (VCP)/p97 is an AAA ATPase molecular chaperone that regulates vital cellular
functions and protein-processing. A recent study indicated that VCP expression levels are correlated with prognosis and
progression of non-small cell lung carcinoma (NSCLC). We not only verified these findings but also identified the specific
role of VCP in NSCLC pathogenesis and progression.
Methodology/Principal Findings: Our results show that VCP is significantly overexpressed in non-small cell lung carcinoma
(NSCLC) as compared to normal tissues and cell lines (p,0.001). Moreover, we observed the corresponding accumulation of
ubiquitinated-proteins in NSCLC cell lines and tissues as compared to the normal controls. VCP inhibition by si/shRNA or
small-molecule (Eeyarestatin I, EerI) significantly (p,0.05, p,0.00007) suppressed H1299 proliferation and migration but
induced (p,0.00001) apoptosis. Cell cycle analysis by flow cytometry verified this data and shows that VCP inhibition
significantly (p,0.001, p,0.003) induced cell cycle arrest in the G0/G1 phases. We also found that VCP directly regulates
p53 and NFkB protein levels as a potential mechanism to control tumor cell proliferation and progression. Finally, we
evaluated the therapeutic potential of VCP inhibition and observed significantly reduced NSCLC tumor growth in both in
vitro and xenograft murine (athymic-nude) models after EerI treatment (p,0.05).
Conclusions/Significance: Thus, targeting VCP in NSCLC may provide a novel strategy to restore p53 and NFkB levels and
ameliorate the growth and tumorigenicity, leading to improved clinical outcomes.
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Introduction
Valosin-containing protein (VCP)/p97 is an ATPase associated
with various cellular activities (AAA) including the cell cycle,
apoptosis, gene transcription, proteostasis, and the DNA damage
response [1,2,3,4]. VCP regulates these diverse functions via the
ubiquitin-proteasome system (UPS). It is a molecular chaperone
that controls retrograde translocation of ubiquitinated substrate
proteins to the proteasome for their degradation [5].
VCP/p97 is associated with the various cellular pathologies and
disease states including neurodegenerative disorders (Creutzfeldt-
Jacob, Alzheimer’s, and Parkinson’s diseases) [6,7], pulmonary
conditions [8] and other protein misfolding disorders [9,10].
Additionally, clinical studies have identified a correlation between
elevated VCP expression and the progression, prognosis, and
metastatic potential of esophageal carcinoma [11], colorectal
carcinoma [12], and prostate cancer [13]. More recently, global
genomic analysis of pancreatic cancer has confirmed VCP
overexpression by Serial analysis of gene expression (SAGE).
Moreover, this study identified VCP as one of the few known
recurrent amplicons at the DNA level associated with tumor
metastasis [14]. Other studies have indicated the generalized role
of UPS in regulating the metastatic potential of pancreatic cancer
[15] and osteosarcoma [16] through the NFkB signaling pathway.
The study on osteosarcoma [16] also indicates the UPS function of
VCP as a regulator of NFkB mediated tumor metastasis.
Elevated VCP expression has also been found to correlate with
the progression and clinical prognosis of non-small cell lung
carcinoma (NSCLC) [17], which accounts for roughly 85% of all
cases of lung cancer. Although lung cancer is the leading cause of
cancer-related mortality in the United States (http://www.
cancer.org/Research/CancerFactsFigures/index), the specific
molecular mechanisms linking VCP expression with NSCLC
pathogenesis and progression have not yet been identified. Thus,
this study was designed to identify the molecular mechanism by
which VCP regulates NSCLC pathogenesis and also evaluate the
therapeutic potential of small-molecule targeting VCP dependent
pathways.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29073Our data demonstrate that VCP inhibition controls NSCLC
proliferation and progression by regulating tumor cell growth,
migration, and apoptosis. We found that VCP inhibition induces
G0/G1-phase cell cycle arrest of NSCLCs. We also identify here
the role of VCP in controlling the protein levels of critical
metastatic regulator- NFkB and tumor suppressor- p53 in
NSCLC. Based on these results, we suggest that VCP regulates
NSCLC tumor- genesis and metastasis via NFkB and p53 by a
UPS-mediated mechanism. Moreover, we found that VCP
inhibition by small molecule significantly (p,0.05) reduced
NSCLC tumor growth in both in vitro and in vivo models. In
summary, we identify and verify the therapeutic potential of a
novel molecular strategy targeting VCP to ameliorate the NSCLC
growth and tumorigenicity.
Materials and Methods
Ethics Statement
All animal experiments were carried out in accordance with the
Johns Hopkins University (JHU) Animal Care and Use Committee
(ACUC) approved protocol (MO11M271). The human lung tissue
sections were collected from Lung Tissue Research Consortium
(LTRC) and JHU pathology core in a blinded manner (without
disclosing the subject’s name and information) and were approved
by the Institutional Review Board (IRB), Johns Hopkins University
as exempt (not a human subject research).
Culture Conditions, Transfections and Treatments
The human bronchial epithelial cells, HBE and Beas2b
(obtained from autopsy of non-cancerous individual, ATCC) were
cultured in MEM and DMEM/F12 medium, respectively. While
human non-small cell lung carcinoma cell lines (adeno-NSCLC,
H1299;p53- and H1944;p53+) and the alveolar adenocarcinoma
NSCLC (A549; p53+) were cultured in RPMI 1640 and DMEM
medium, respectively. The media were supplemented with 10%
Fetal Bovine Serum (FBS) and 1% Penicillin, Streptomycin,
Amphotericin B (PSA) from Invitrogen and cells were grown in an
incubator at 37uC with 5% CO2. The cells were transiently
transfected with Lipofectamine 2000 (Invitrogen) following the
manufacturer’s instructions. To inhibit VCP expression in
H1299/H1944 cells by RNA interference, short hairpin RNAs
(shRNAs) targeting the sequence of VCP cloned into the pSHAG-
MAGIC2 (pSM2) vector (Open Biosystems)were used. The VCP
shRNA (0.2 mg for 96-well; 1.6 mg for 12-well; 4 mg for 6-well)
knock down efficiencies were compared to empty vector (at same
concentration as VCPshRNA) transfected control cells. In
addition, Dharmacon ON-TARGETplus SMARTpool of VCP
siRNA (Thermo Scientific; 100 nm) was used to verify VCP
inhibition data as compared to the control siRNA (100 nm).
While, VCP function was inhibited by small molecule VCP
inhibitor Eeyarestatin I (EerI) [18] at a final concentration of
10 mM for 24 hrs and compared to DMSO control vehicle. The
pcDNA3.1-VCP-myc and control plasmids were transfected as
above for over expression experiments.
Immunofluorescence Microscopy of Clinical Biopsies
from NSCLC Patients-
Formalin-fixed, paraffin-embedded longitudinal tissue sections
from adeno- and squamous- NSCLC human subjects were used to
evaluate the localization and expression of VCP and ubiquitin in
tumor and surrounding control tissue. Tissues were immuno-
stained with primary antibodies (1:200 dilution) for VCP (rabbit
polyclonal, Santa Cruz Biotechnology [SCBT]) and ubiquitin
(mouse monoclonal, SCBT) followed by secondary antibodies
(1:200 dilution) using our previously described protocol [19]. The
secondary antibodies used were goat anti-rabbit IgG FITC
(SCBT) and donkey anti-mouse Dylight 594 (Jackson ImmunoR-
esearch). Nuclei were detected by Hoechst (Invitrogen) staining.
Images were captured by Axiovert 200 Carl Zeis Fluorescence
microscope using the Zeiss Axiocam HRC camera and Axiovision
software.
Immunoblotting and Immunoprecipitation
All immunoblotting (IB) and immunoprecipitation (IP) exper-
iments were performed as described previously [19]. Briefly, total
protein extracts were prepared from the control and NSCLC cell
lines or transfected cells using 16Mammalian protein extraction
reagent (M-PER, Pierce) supplemented with protease inhibitor
cocktail (Sigma) and 5 mM EDTA (Sigma). Protein extracts were
then resolved by SDS-PAGE followed by IB with antibodies
against VCP (1:500, SCBT), p53 (1:500, SCBT), NFkB (1:500,
SCBT), ubiquitin (1:1000, SCBT), Nrf2 (1:500, SCBT), SIRT-1
(1:250, SCBT), and b-actin (equal loading control, 1:2500, Sigma).
Proteins were detected with the HyGlo
TM Chemiluminescent
HRP Antibody Detection Reagent and exposed to HyBlot CL
TM
Autoradiography film (Denville Scientific). To examine the
binding of p53 to VCP, we incubated two aliquots of 500 mg/ml
total protein extract with 50 mL of protein A/G PLUS-agarose
beads (SCBT) for 3 hours at 4uC. After pre-clearing, 1 mgo f
mouse VCP antibody was added to one tube, and pre-immune
serum was added to the other tube as a negative control. After
1 hour, the agarose beads (50 mL) were added to each tube
followed by overnight incubation at 4uC. The beads were washed
three times with ice cold PBS followed by heating at 100uC for 2–
3 minutes in loading dye containing b-mercaptoethanol. The IP’s
were resolved by SDS-PAGE and immunoblotted using rabbit p53
antibody (as above) to identify the protein-protein interaction.
Cell Proliferation Assay
Cell growth was quantified by MTT (3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) assay as described previously
[20]. Briefly, H1299 cells were seeded onto 96-well plates at a
concentration of 2500 cells/well, followed either by treatment with
EerI (10 mM) or DMSO (vehicle), or transfection with VCP- or
control-siRNA. After 22- (inhibitor) or 14- (transfected) hours of
incubation, 10 ml of 5 mg/ml MTT reagent (Cell Titer 96H
AQueous One Solution, Promega) was added to each well. The cells
incubated for at least 2 hours with MTT followed by analysis of
absorbance (490 nm) using a VERSAmax microplate reader
(Molecular Devices) at the indicated time points.
Flow Cytometry-Based Cell-Cycle Analysis-
H1299 cells (1610
6) were treated with EerI (10 mM) and
DMSO (vehicle) for 24 hours or were transfected with
VCPshRNA and pSM2 control vector for 48 hours. Cells were
rinsed with PBS and subsequently fixed in ice-cold ethanol (70%
v/v) overnight. The fixed cells were then washed twice with by
PBS followed by re-suspension in a staining solution containing
10 mg/ml propidium iodide (PI; Sigma), 20 mg/ml RNAse A
(Sigma), and BSA (0.1%w/v). After a 1-hour incubation at room
temperature, DNA content was determined using a FACScan flow
cytometer (BD Biosciences) as described previously [21]. Cell-cycle
distribution was analyzed using Cell Quest software (BD
Biosciences). Red fluorescence (582642 nm) was evaluated on a
linear scale after pulse-width analysis was used to exclude cell
doublets and aggregates from analysis. Cells with DNA content
between 2 N and 4 N were then designated as being in the G0-/
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each phase were determined.
Caspase-3/7 Enzyme Assay-
Apoptotic activity was also quantified using the Caspase-3/7
Glo Assay Kit (Promega), as described previously [22]. Briefly,
H1299 cells were seeded onto a 96-well, black-bottomed plate at a
concentration of 2500cells/well in 100 ml culture medium and
allowed to adhere overnight. Cells were then treated with EerI
(10 mM) or DMSO (vehicle) or transfected with VCP shRNA or
control plasmid for indicated time points as above. Subsequently,
100 ml of the freshly prepared caspase-3/7 reagent was added,
followed by 1 hour incubation at room temperature. Lumines-
cence was quantified using a Spectramax microplate reader
(Molecular Devices, excitation- 498 nm and emission- 521 nm).
Cell Scratch Assay-
H1299 cells were transfected with VCPshRNA and pSM2
control vector so as to form a fully confluent monolayer on a 12-
well plate. After 36 hours, a p10 pipette tip was used to create a
,2 cm scratch on the monolayer. Cells were washed twice with
PBS to remove all debris and then washed with RPMI 1640
media. Alternatively, a scratch was created on a fully confluent
monolayer, followed by PBS washes, and treatment with either
EerI (10 mM) or DMSO (vehicle). The cells were then allowed to
proliferate and migrate for the following 24 hours. Images were
collected 8, 12 and 24 hours after the scratch (assigned time
0 hours) using a Nikon Eclipse TS100 inverted light microscope
with a 106 phase objective and Infinity Capture software.
Changes in the width of the scratches over time were later
analyzed using Adobe Photoshop software.
Transwell Invasion Assay
H1299 cells were transfected with control pSM2 vector or
VCPshRNA-2 plasmid for 24 hours. Cells were then trypsinized
and plated (5000 cells) on Matrigel (BD Biosciences, 200 mg
Matrigel in 400 ml serum-free medium) coated transwell inserts
(0.4 mm pores, Millipore). After 24 hrs, cells that had migrated
through and adhered to the bottom surface of the insert were
stained with Trypan Blue (Life Technologies) and counted under a
light microscope.
In vitro Tumor Cell Growth Model-
RPMI-1640 medium supplemented with 10% fetal bovine
serum and 0.6% of agarose (Research Products International) was
prepared and poured into each well of a 6-well plate as a base agar
layer. H1299 cells (4610
5) were then suspended in 0.3% molten
agarose and layered on top of the solidified base agar in each dish.
These dishes were placed at 37uC and 5% CO2 in a cell culture
incubator for 1 hour to allow the top layer to solidify. Fresh
RPMI-1640 media containing either EerI (10 mM) or DMSO
(vehicle) was then layered on top to treat the cells (n=3) and
prevent the agarose from drying. The plates were returned to the
cell culture incubator at 37uC and 5% CO2 for 48-hours. Images
of each well were captured and densitometry analysis was
performed using Image J software to quantify statistical changes
in tumor cell growth.
Xenograft Model
All animal experiments were carried out in accordance with the
Johns Hopkins University Animal Care and Use Committee
(ACUC) approved protocols. We used age-, weight-and sex-
matched (8–10 weeks old) athymic nude mice (NCI Animal
Production Program). All mice were housed in controlled
environment and pathogen-free conditions. Briefly, H1299 cells
(8610
6) were suspended in 100 ml PBS media containing Matrigel
(1:1 v/v, BD BioSciences) and subsequently injected subcutaneously
(s.c.) into the sub-scapular region of the mice. After two days, mice
were randomized into treatment and control groups (n=5) and
given either 50 mg EerI in 100 ml PBS or appropriate DMSO
vehicle (0.01% v/v) by s.c. injection directly into the tumor. Drug
treatment was repeated on day-6. Tumor size was determined by
measurement of the largest and perpendicular diameters every week
till week-6 followed by terminal euthanasia following procedures of
our ACUC approved protocol. Tumor volume (V) was calculated
according to the formula V=0.52 ab
2, where ‘‘a’’ is the largest
superficial diameter and ‘‘b’’ is the diameter orthogonal to ‘‘a’’.
Statistical and Image Analysis-
Representative data is shown as the mean 6 SEM of at least
three experiments. Variations in data between the different groups
were tested by a two-tailed unpaired t-test. A p-value less than 0.05
was considered significant. Changes in protein expression were
analyzed by densitometry using the Image J 1.386software (NIH,
Bethesda, MD).
Results
Proteostasis-imbalance Induces VCP Expression in
Adeno- and Squamous- NSCLC
A previous clinical study has indicated that elevated VCP
protein expression is a prognosticator for overall survival in both
early and advanced pathologic stages (pT) of non-small cell lung
carcinoma (NSCLC) [17]. To substantiate these findings, we first
analyzed human NSCLC tissue samples for changes in VCP
protein levels by immunofluorescence microscopy. Our data not
only confirm significantly elevated VCP protein expression but
also demonstrate the accumulation of ubiquitinated proteins
(p,0.001) in both adeno(AD)- and squamous(SQ)-NSCLC as
compared to the surrounding non-neoplastic control lung tissue
(Figure 1a). We anticipate that accumulation of ubiquitinated
proteins is due to the reduced proteasomal activity as reported
earlier for other cancer tissues [23]. Moreover, we found that VCP
and ubiquitin are co-localized in peri-nuclear aggregates in these
tissues (Figure 1b, representative areas). These findings, suggest a
causative role of proteostasis deficiency in NSCLC indicating that
the accumulation of ubiquitinated proteins resulting from
proteostasis-imbalance [8,10] induce VCP expression in NSCLC.
Although elevated VCP expression has been correlated to
probability of survival for NSCLC patients [17], its functional
role in NSCLC is not apparent.
VCP Regulates NSCLC Proliferation and Apoptosis
To investigate the role of VCP in the pathogenesis and
progression of NSCLC, we inhibited VCP expression or function
Figure 1. Elevated VCP protein levels and proteostasis-imbalance in NSCLC. (a) We examined the expression of VCP in adeno(AD)- and
squamous(SQ)-NSCLSC as compared to normal tissue and observed a significant increase (p,0.001) in VCP expression and ubiquitin accumulation in
both NSCLCs (n=4, White bar=100 mm). (b) We confirmed that VCP and ubiquitinated proteins are co-localized in peri-nuclear aggregates of these
tissues (n=4, Black bar=100 mm & Red bar=10 mm). Elevated VCP protein expression and ubiquitin accumulation in NSCLC indicates proteostasis-
imbalance.
doi:10.1371/journal.pone.0029073.g001
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PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e29073Figure 2. VCP regulates NSCLC proliferation, apoptosis and cell division. (a) H1299 cells were seeded on a 96-well plate and either
transfected with pSM2 control vector or VCP-shRNA (for 16 hrs) or treated with EerI (10 mM) or DMSO (vehicle) for 24 hrs. Promega Aqueous One MTS
reagent was added to each well, 2 hours before stopping the experiment and VERSAmax microplate reader was used to quantify the MTS activity
(n=4) at indicated time points. Our data shows a significant (p,0.01) decrease in cell proliferation by VCP inhibition. (b) H1299 cells were seeded on
a black-bottomed 96-well plate and either transfected with pSM2 control vector or VCP-shRNA or treated with EerI or DMSO. After 48 (VCP-shRNA) or
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and cell cycle. First, we used cell proliferation assays to quantify
changes in proliferation induced by VCP inhibition. Our data
shows that inhibition of VCP protein expression by VCP siRNA
significantly (p,0.05) reduced H1299 proliferation as early as
16 hours of transfection (Figure 2a, top panel). Similarly,
treatment with a functional inhibitor of VCP, Eeyarestatin I
(EerI, 24 hrs), significantly (p,0.01) reduced H1299 proliferation
(24.0%) as compared to the vehicle-treated control (Figure 2a,
bottom panel).
We then examined the effect of VCP inhibition on apoptosis of
H1299 cells by a TUNEL assay (Methods S1). We observed an
increase in the number of TUNEL-positive (green, apoptotic) cells
by shRNA mediated VCP inhibition as compared to controls
transfected with empty pSM2 vector (Figure S1, left panel,
representative images). The TUNEL results were quantified by
randomly selecting and analyzing 100 cells per sample (n=3) and
then calculating the average number of apoptotic cells. Our data
(Figure S1, right panel) shows a significant 6-fold increase
(p,0.00001) in the number of TUNEL-positive cells after VCP
knockdown as compared to the controls. To confirm these
findings, we quantified the changes in caspase-3/7 enzymatic
activity after VCP inhibition. Caspase-3/7 are key mediators of
apoptosis, and their activity offers a highly quantitative means for
measuring cellular apoptosis. Our results indicate that knockdown
of VCP expression by VCP-shRNA2 significantly (Figure 2b, top
panel, p,0.05) increased caspase activity compared to the
controls. Moreover, functional disruption of VCP-mediated
proteasomal degradation by EerI caused a significant (,2-fold,
Figure 2b, bottom panel, p,0.00001) increase in caspase-3/7
activity relative to vehicle-treated controls. Our findings suggested
that VCP regulates NSCLC proliferation and apoptosis and
indicate its critical role in regulating the tumor cell cycle.
VCP Regulates Cell Division of NSCLC
Next, we investigated the role of VCP in regulating the NSCLC
cell cycle. For these experiments, we inhibited VCP expression or
function in H1299 cells as above to quantify changes in cell cycle
distribution by propidium iodide staining and flow cytometry.
Transient transfection with VCP-shRNA2 (Figure 2c) significantly
(p,0.001) induced a G0/G1-phase arrest (,11%). This is
confirmed by the significant (p,0.01) decrease in the number of
cells in the S- phase (,7%) as compared to the control. Our data
demonstrates a more substantial change after selective inhibition
of the ERAD (endoplasmic reticulum-associated degradation)
function of VCP by EerI treatment (Figure 2d). We found that
EerI treatment induced G0/G1-phase arrest (,13%, p,0.01)
with corresponding decreases in the relative number of cells in the
S- (,4%, p,0.05) and G2/M-phases (7%, p,0.01) as compared
to the vehicle treated control. Although in both cases VCP
inhibition triggered G0/G1-phase growth arrest and reduced the
number of cells undergoing DNA replication in the S-phase, only
inhibition of VCP-mediated proteasomal degradation by EerI
reduced the number of cells actively undergoing mitosis in the G2/
M-phase. Our data demonstrates the critical role of VCP in
regulating tumor cell cycle, suggesting its involvement in NSCLC
progression and invasion.
VCP Mediates NSCLC Migration, Invasion and Tumor
Growth
VCP has been shown to regulate NFkB signaling, which is
critical for the metastasis of osteosarcoma cell line [16]. Hence, we
anticipated that VCP might play a critical role in NSCLC
migration, invasion, and metastasis. We tested this hypothesis by
first quantifying changes in NSCLC migration and invasion after
VCP knockdown or inhibition as described above. Knockdown of
VCP expression (Figure 3a, representative images) reduced
migration and invasion of H1299 cells into the scratch as
compared to the controls. The distances remaining between the
edges of the wounds (n=3) were then quantified using Infinity
Analyze software (Figure 3a, bottom panel). Quantification data
confirms that VCP inhibition significantly (p,0.05) delayed the
migration and invasion of the H1299 cells into the scratch as
shown after 12 and 24 hours relative to the controls. We observed
the same result with functional inhibitor of VCP, EerI (Figure 3b),
further confirming the critical role of VCP in regulating NSCLC
migration and invasion.
To verify these findings, we quantified the effect of VCP
inhibition on NSCLC migration and invasion by transwell
invasion assay of H1299 cells. H1299 cells were transfected with
VCP-shRNA2 or pSM2 for 24 hours as above, followed by
trypsinization and plating of 5000 cells in serum-free medium on a
transwell insert coated with Matrigel. After 24 hours, we stained
(Trypan Blue Dye) cells that had invaded through the Matrigel to
the bottom of the membrane and counted the total number of cells
in a 106 magnification field for all replicates. Our results show
that VCP inhibition significantly (p,0.05) reduced the number of
invading cells by ,26% as compared to controls (Figure 3c). We
also identified the critical role of elevated VCP expression in
promoting tumor growth using the in vitro tumor growth model
(described in the Materials and Methods). Briefly, H1299 cells
(4610
5) were seeded into each well of a six-well plate (n=3)
containing a matrix composed of two layers of agarose [0.6%
(bottom) and 0.3% (top)]. Our data shows that treatment of these
cells with EerI significantly reduced in vitro tumor cell growth
(Figure 3d, p,0.01). The data clearly shows the overall reduction
in tumor cell growth (Figure 3d, representative images). Our
results demonstrate the critical role of VCP in promoting NSCLC
migration and invasion, implicating VCP in tumor metastasis.
VCP Regulates Tumor Suppressor p53 and NFkB Protein
Levels
Next, we identified the molecular mechanism by which VCP
induces NSCLC pathogenesis and metastasis. We used NSCLC
(A549, H1299, and H1944) and non-neoplastic control (HBE and
Beas2b) cells to identify changes in expression levels of VCP,
ubiquitin, and tumor associated proteins including tumor
24 (EerI) hours, caspase-3/7 activity was quantified using the luminescence substrate (Promega). Our data shows an increase in caspase-3/7 activity
after transient VCP knockdown (* p,0.05) and a very significant increase (two-fold) in caspase-3/7 activity after treatment with functional inhibitor of
VCP, EerI (*** p,0.00001). Next, (c) H1299 cells were either transfected with VCP-shRNA2 and pSM2 control vector or (d) treated with EerI or DMSO.
Cells were then fixed in 70% ethanol followed by propidium iodide (10 mg/ml) staining for 1 hour. The profiles of DNA content (measured by a
FACScan flow cytometer) for cell-cycle distributions are shown. Our data, summarized in the bar graph (bottom of each panel), shows that VCP
knockdown induced G0/G1 arrest (*** p,0.001) and reduced the number of cells undergoing DNA replication (S-phase; ** p,0.01). Inhibition of
VCP’s function by EerI not only induced G0/G1 arrest (** p,0.01) and decreased DNA replication (** p,0.01) but also significantly reduced the
number of cells undergoing mitosis (G2/M-phase; * p,0.05). VCP inhibition controls the tumorigenic capacity of NSCLC by slowing proliferation and
division while simultaneously inducing apoptosis.
doi:10.1371/journal.pone.0029073.g002
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PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e29073Figure 3. VCP inhibition retards the migration, invasion and growth of NSCLC. H1299 cells were either (a) transfected with pSM2 control
vector or VCP-shRNA or (b) treated with EerI or DMSO, followed by scratch assay to quantify changes in cell migration. Briefly, a scratch was made
across the center of the confluent monolayer using a 10 ml pipette tip. The cells were allowed to migrate and were monitored at the indicated time
points using a Nikon light microscope and Infinity Capture Software. The representative images show that both VCP knockdown and inhibition visibly
slowed H1299 migration into the scratch by 12 and 24 hours (top panels). Changes in the average width of the scratch were calculated using Infinity
Analyze Software (mean 6 SEM; n=3–4). Quantitative analysis show that both VCP knockdown and functional inhibition significantly retarded cell
migration at 12 and 24 hours (bottom panels, * p,0.05; ** p,0.0005). (c) H1299 cells were transfected with pSM2 or VCPshRNA2 for 24 hours and
transferred to transwell inserts (BD, 0.4 mm pores) coated with 200 mg Matrigel basement matrix for additional incubation for 24 hours. Following
incubation, cells that had migrated to the bottom of the membrane were stained with trypan blue solution and the central field of each insert was
visualized using a Nikon light microscope (n=4, mean 6 SEM given). The data shows that VCP inhibition significantly reduced the number of
invading cells as compared to the controls. (d) H1299 cells (4.0610
5 cells/well) were suspended in 2 mL of serum-containing medium with agarose
(0.3%) and immediately plated over a layer of solidified agarose (2-mL, 0.6%) on a 6-well plate (n=3). No cells (Blank) and untreated H1299 cells were
used as controls. Fresh media containing either EerI (10 mM) or DMSO (vehicle) was added on top. After 48 hrs, the images were captured and
analyzed using the Adobe Photoshop Software. Representative images and densitometry data (mean 6 SEM) shows the significant decrease in
number of colonies and H1299 cell invasion in agarose by EerI treatment as compared to the DMSO treated controls. VCP mediates NSCLC migration,
invasion and growth that suggest its critical role in tumor cell progression and metastasis.
doi:10.1371/journal.pone.0029073.g003
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factor 2 (Nrf2) [26], and sirtuin1 (SIRT1) [27]. Our data verifies
significantly elevated VCP expression and the accumulation of
ubiquitinated proteins (aggregates) in NSCLC (Figure 4a) as
compared to the control cells, in accordance with our findings
from the lung tumor tissues (Figure 1). Moreover, we identify here
a correlation between VCP overexpression (highest expression)
and induction of tumor associated proteins- NFkB, Nrf2 and
SIRT1, and down regulation of tumor suppressor-p53 in NSCLC
(H1299&H1944) cell lines (Figure 4a), suggesting the critical role
of VCP-mediated proteasomal degradation in tumor cell prolifer-
ation and metastasis.
VCP has been shown to regulate NFkB suggesting its role in
tumor metastasis [16]. We anticipated that a similar mechanism
was responsible for the pro-metastatic function of VCP in NSCLC
as it is known to regulate the NFkB protein levels by mediating the
proteasomal degradation of its endogenous inhibitor, IkB [16]. To
verify this, we overexpressed VCP in H1299 cells and observed
changes in the protein levels of the critical metastatic mediator,
NFkB. We observed a corresponding upregulation of NFkBa s
compared to controls (Figure 4b), confirming our hypothesis that
VCP mediates NSCLC metastasis by regulating the NFkB
signaling pathway. Next, we further investigated whether VCP
may also regulate the levels of critical tumor suprresor-p53 by a
similar mechanism. We used H1944 cells for this experiment as
H1299 cell line is p53 deficient [28,29]. We observed that
inhibition of VCP expression levels in H1944 cells significantly
upregulates tumor suppressor p53 by VCP inhibition (Figure 4c).
We also verified the decrease in NFkB by VCP inhibition. These
results suggest that VCP may regulate p53-NFkB protein levels by
mediating its proteasomal degradation of p53 and IkB, an
endogenous inhibitor of NFkB. To substantiate this finding, we
used immunoprecipitation to determine whether p53 and VCP
interact in NSCLC cells. Our results demonstrate a novel VCP-
Figure 4. VCP regulates protein levels of p53, NFkB and other cancer-related proteins. (a) We observed the accumulation of ubiquitinated
proteins, induction of VCP, Nrf2, SIRT1 (Sirtuin 1, stress regulator), and NFkB, and suppression of p53 in NSCLC cell lines (H1299 and H1944) as
compared to control (Beas2b and HBE) cells indicating towards proteostasis-imbalance. b-actin antibody was used as an equal-loading control. NFkB,
p53, Nrf2 and SIRT1 are known to be involved in tumor metastasis, proliferation, apoptosis and inflammatory-oxidative stress responses. (b) VCP
overexpression (VCP-myc) in H1299 cells shows an increase in NFkB protein levels. (c) H1944 cells transfected with VCP shRNA (lane 4–6) show a
significant increase in p53 protein levels and decrease in NFkB, as compared to pSM2 control (lanes 1–3). VCP immunoblot verifies VCP inhibition
while b-actin shows equal loading. (d) Co-immunoprecipitation (IP) of p53 with VCP antibody verifies the novel protein-protein interaction. IP lacking
anti-VCP antibody was used as a negative control. Regulation of oncogene and tumor suppressor by VCP provides a potential mechanism for its critical
role in tumor progression and metastasis.
doi:10.1371/journal.pone.0029073.g004
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mediates proteasomal degradation of p53, as previously shown for
IkB [30,31]. To summarize, we demonstrated that VCP regulates
NFkB and p53 protein levels as a potential mechanism to control
NSCLC pathogenesis and progression.
VCP Inhibition Controls Tumor Growth in NSCLC-
Xenograft Model
We established NSCLC tumors in the subscapular region of
athymic nude mice by subcutaneous (s.c.) injection of H1299 cells
(8610
6) complexed with Matrigel. The mice were treated with
functional inhibitor of VCP, EerI (10 mM or DMSO vehicle
control) at indicated times on the scale (Figure 5a) and tumor
volume was monitored every week (n=5). Our data shows that
EerI treatment significantly reduced tumor growth as compared to
the DMSO vehicle control (Figure 5b & c). We observed consistent
and significant reduction in primary tumor volume in EerI-
treatment group (Figure 5b, p,0.05). This finding demonstrate
the therapeutic potential of VCP inhibitor(s) in controlling
NSCLC pathogenesis and progression; we are currently standard-
izing the dose and selective delivery of a novel VCP inhibitor
based on its ability to control NSCLC progression and metastasis.
Discussion
VCP is overexpressed in many solid tumors, including prostate
and pancreatic cancers [13,32], esophageal and colorectal
carcinomas [11,12], osteosarcoma [16]. Recent studies have also
Figure 5. Inhibition of VCP’s function by EerI reduces tumor growth in NSCLC-xenograft model. (a) Tumors were established in athymic
nude mice by subcutaneous (s.c.) injection of H1299 (8610
6) cells complexed with Matrigel into the upper left flank. Mice were randomized into two
groups (n=5) and treated with EerI (50 mg, 2 doses at indicated times as on the scale) or DMSO vehicle. (b) Primary tumor growth was measured
volumetrically over time and statistical analysis of data is shown as mean 6 SEM. EerI treatment significantly reduced tumor volume as compared to
the DMSO vehicle control ** p,0.01). (c) Representative images captured on Day 8 illustrate the difference in tumor volumes between the two
groups. VCP can be therapeutically targeted using EerI or other potent VCP-inhibitor to control NCLSC tumor growth and/or progression.
doi:10.1371/journal.pone.0029073.g005
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factor for overall survival in non-small cell lung carcinoma
(NSCLC) [17,33]. We verified elevated VCP protein expression
not only in human adeno(AD)- and squamous(SQ)-NSCLC tissues
(Figure 1) but also in the NSCLC cell lines A549, H1229 and
H1944 (Figure 4a) as compared to non-cancer, HBE (.5-fold) or
Beas2b ($2-fold) cell lines. In addition to genetic changes, VCP
expression can also be influenced by cigarette smoke exposure
and/or age [34,35] (pathogenetic changes, Figure 6). The elevated
VCP expression has several pathogenic consequences, it is a major
component of retrograde translocation machinery that pulls out
ubiquitinated protein from ER membrane to proteasome for
degradation [9]. The increased VCP retrograde translocation
activity may explain the significant accumulation of ubiquitinated
proteins in NSCLC (Figures 1 & 4a). We anticipate that the peri-
nuclear cytosolic accumulation of ubiquitinated proteins (aggre-
somes) further stimulates VCP expression, leading to a chronic
VCP induction (Figure 6). We designed this study to not only
verify the elevated VCP protein expression in adeno- and
squamous- NSCLC but also identify if it is involved in tumor
pathogenesis and progression.
We performed a series of in vitro functional studies using VCP
knockdown (RNAi) and a functional inhibitor (EerI) to assess the
molecular links between chronic VCP induction and NSCLC
pathogenesis. Our data suggest that VCP regulates a number of
critical cellular processes involved in NSCLC tumor development,
growth and metastasis. We found that inhibition of VCP protein
expression or function reduced the proliferative capacity of
NSCLC cells and induced apoptosis (Figure 2a & b), caused
G0/G1-growth phase arrest (Figure 2c & d) and slowed NSCLC
migration and invasion (Figure 3). Although we are the first to
demonstrate the role of VCP in regulating key cellular processes in
NSCLC, our findings are consistent with previous studies in yeast,
C. elegans and non-neoplastic cells studying cell proliferation and
apoptosis [1,9]. In addition to proliferation and apoptosis, we
found that VCP also mediates tumor cell migration and invasion
suggesting its critical role in NSCLC pathogenesis and progres-
sion. Moreover, each of these processes is considered to be one of
several key ‘‘hallmarks of cancer’’ – distinctive and complimentary
capabilities that must be acquired by cells to enable tumor growth
and metastasis [36]. Coupled with the evidence that VCP is
essential for cancer cell survival (Figure 2), it is clearly an attractive
molecular target for controlling tumor genesis and metastasis of
NSCLC and other forms of cancers because its successful
inhibition may control multiple critical stages involved in tumor
formation and progression.
In order to determine the molecular mechanism by which
elevated VCP expression promotes these various cellular processes
involved in NSCLC pathogenesis and progression, we examined
the expression the levels of several cancer-related proteins. We
observed the significant induction of Nrf2 and SIRT1 and
suppression of p53 in NSCLC cell lines (H1299 and H1944) as
compared to control (Beas2b and HBE) cells (Figure 4a). Further
experimental analysis revealed that VCP not only participates in
the proteasomal degradation of tumor suppressor p53 but also
forms a complex with p53 that can be detected by immunopre-
cipitation (Figure 4b & c). This finding confirms and adds to a
previous study that suggested that RNAi of VCP may rescue p53
from proteasomal degradation in HeLa cells [37]. Moreover, our
data suggests that VCP regulates p53 levels by proteasomal
degradation pathway. Although, p53 is known to be degraded by
the proteasomal pathway [38,39] but we show here for the first
time the critical intermediate involved in this process (Figure 4d).
Further studies are required to identify the precise mechanism of
VCP mediated p53 degradation. Nonetheless, we found here that
VCP regulates protein levels of p53, the principal tumor
suppressor that is a transcription factor capable of activating
genes involved in cell cycle regulation, apoptosis and countless
other processes [40,41,42]. This may also explain anti-proliferative
and pro-apoptotic effects of VCP inhibition in NSCLC (Figures 2
& 6). We also confirm (Figure 4b) here the well-characterized role
of VCP in regulating NFkB levels, a key metastasis mediator
[9,16]. Elevated VCP expression in NSCLC likely leads to
increased proteasomal degradation of IkB, the endogenous
inhibitor of NFkB, explaining NFkB-induced pro-survival/anti-
apoptotic signaling. Recent evidence also suggested that VCP
and/or its associated co-factors are also implicated in the direct
regulation of HIF1a (hypoxia-inducible factor 1a; tumor angio-
genesis and metastasis promoter) [43], Nrf2 [8] and Aurora B
kinase (implicated in genomic instability) [44]. Clearly VCP
inhibition can restore p53 and NFkB protein expression based on
Figure 6. Schematic summarizing the functional role of VCP in
NSCLC pathogenesis and progression. Our data suggests that
elevated VCP expression and subsequent accumulation of ubiquiti-
nated proteins (proteostasis-imbalance) de-regulates NSCLC prolifera-
tion, cell cycle, apoptosis and migration via NFkB and p53 pathways
resulting in increased tumor- genesis and metastasis. We predict that
increased retrograde translocation rates results in the accumulation of
ubiquitinated aggregates that leads to chronic activation of VCP. This
chronic VCP induction may lead to the pathological expression of key
cancer-related proteins, including inhibition of tumor suppressor p53
and activation of key metastasis-protein NFkB, as seen in our study. We
propose that inhibition of VCP expression and/or function may control the
progression and aggressiveness of NSCLC by rescuing vital cellular
pathways from pathogenic activation.
doi:10.1371/journal.pone.0029073.g006
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in treating tumor progression and metastasis.
In conclusion, we report for the first time a thorough analysis of
the molecular links between elevated VCP protein expression and
NSCLC pathogenesis and progression. VCP over expression may
facilitate malignancy by promoting NSCLC cell growth, prolifer-
ation, migration and anti-apoptosis through abnormal expression
of several cancer-related proteins, including p53 and NFkB.
Moreover, we demonstrate the therapeutic potential of targeting
VCP by a small-molecule functional inhibitor (EerI, Eeyarestatin I)
using, in vitro and murine models (Figures 3d & 5). Recent studies
have revealed that EerI binds to both VCP and the ER
(endoplasmic reticulum) membrane and inhibits VCP-dependent
protein degradation as well as VCP-associated deubiquitinating
enzymes [18,45]. We would like to emphasize that EerI or another
potent VCP inhibitor may have added potential as a novel cancer
therapeutic over existing proteostasis and HDAC (histone
deacetylase) inhibitors [such as the FDA-approved drugs bortezo-
mib/PS-341 [46] and SAHA [47]] as its targets upstream VCP-
retrograde translocation step prior to proteasomal and HDAC6
mediated protein processing as we recently discussed [9,35]. Based
on the dual therapeutic potential of VCP inhibition as well as its
ability to regulate critical oncogene and tumor suppressor protein
levels, we are currently evaluating its therapeutic efficacy in
controlling NSCLC metastasis using an intrapulmonary tumor
implantation murine model.
Supporting Information
Figure S1 VCP regulates apoptosis of NSCLC. TUNEL
assay of H1299 cells transfected with pSM2 control or
VCPshRNA (for 48 hrs) was used to identify number of apoptotic
cells. Nuclear (blue, Hoescht) and TUNEL (green) staining of
representative areas of each treatment is shown (white
bar=200 mm). We observed a 6-fold increase in the number of
TUNEL-positive cells by VCP inhibition (shRNA-2&-3) as
compared to control (pSM2). VCP inhibition controls the tumorigenic
capacity of NSCLC by inducing apoptosis.
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Methods S1 Terminal Transferase dUTP Nick-End
Labelling (TUNEL) Assay.
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